Similarly, expression of any of the MEK mutants conferred substantial resistance to a MEK inhibitor (selumetinib) on the tumor cells, with concentrations required to achieve 50% growth inhibition (GI50) being more than 10-fold higher than that observed in control cells (Supplementary Fig. 2e, f). The gene discussed is MAP2K7; the disease is neoplasm.